• The recent study which showed that erythropoietin stimulating agents do not reduce cardiac (or renal) events in diabetic nephropathy patients with anemia-
  • The prostacyclin analog which has been recently shown to prevent contrast induced nephropathy in renal insufficiency patients undergoing coronary angiography or intervention-
  • The glucagon-like peptide-1 (GLP-1) which was recently shown to decrease obesity in non-diabetics also-
  • The recent study which showed that ICDs do not reduce total mortality in early MI with low ejection fraction or other high risk criteria (similar results as in the DINAMIT trial)-
  • The recent study which showed that empirical antiarrhythmic drug therapy after ablation therapy for paroxysmal AF reduces clinically significant atrial arrhythmias-
  • The selective endothelin-receptor antagonist which was recently shown to be effective in treatment-resistant hypertension-
  • The recent trial which showed endovascular repair of abdominal aortic aneurysms, when compared with surgical repair, has lower perioperative mortality and similar mid-term (2 yr) mortality-